Amarin Corporation PLC (AMRN) Announces Additional Effects of Vascepa® on Lipoprotein Particle Concentration From the ANCHOR Study Presented at the National Lipid Association 2013 Annual Scientific Sessions
5/30/2013 10:04:25 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today presented additional data on Vascepa® (icosapent ethyl) and its effect on lipoprotein particle concentration from the Phase 3 ANCHOR study at the National Lipid Association (NLA) 2013 Annual Scientific Session in Las Vegas, Nevada.
Help employers find you! Check out all the jobs and post your resume.
comments powered by